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Abstract
Background: Post-operative hepatic dysfunction is a major cause of concern when undertaking a liver
resection. The generation of reactive oxygen species (ROS) as a result of hepatic ischaemia/reperfusion
(I/R) injury can result in hepatocellular injury. Experimental evidence suggests that N-acetylcysteine may
ameliorate ROS-mediated liver injury.
Methods: A cohort of 44 patients who had undergone a liver resection and receiving peri-operative
N-acetylcysteine (NAC) were compared with a further cohort of 44 patients who did not. Liver function
tests were compared on post-operative days 1, 3 and 5. Peri-operative outcome data were retrieved from
a prospectively maintained database within our unit.
Results: Administration of NAC was associated with a prolonged prothrombin time on the third post-
operative day (18.4 versus 16.4 s; P = 0.002). The incidence of grades B and C liver failure was lower in
the NAC group although this difference did not reach statistical significance (6.9% versus 14%; P =
0.287). The overall complication rate was similar between groups (32% versus 25%; P = ns). There were
two peri-operative deaths in the NAC group and one in the control group (P = NS).
Conclusion: In spite of promising experimental evidence, this study was not able to demonstrate any
advantage in the routine administration of peri-operative NAC in patients undergoing a liver resection.
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Introduction
Hepatic resection is increasingly utilized to treat a variety of both
benign and malignant diseases. One of the major causes of post-
operative morbidity is the development of post-hepatectomy liver
failure (PHLF), the frequency of which increases as the remnant
liver volume decreases.1 In addition, the presence of background
abnormalities in the hepatic parenchyma (e.g. chemotherapy
associated liver injury, steatohepatitis, fibrosis/cirrhosis) increases
the risk of developing PHLF.2–5
Vascular clamping of the hepatic inflow (and on occasion
outflow) is commonly utilized during major hepatic surgery to
minimize intra-operative blood loss and to facilitate parenchymal
transection. These periods of vascular exclusion can result in
hepatic ischaemia/reperfusion (I/R) injury which is associated
with oxidative stress and depletion of intracellular ATP.6–8
Glutathione (GSH) is a key anti-oxidant within the liver that is
depleted after I/R injury.9 GSH can be synthesized by tissues in
response to a variety of insults from the amino acids glycine,
glutamic acid and cysteine. It is the availability of cysteine which is
most often the rate limiting step in the de novo synthesis of GSH.10
N-acetylcysteine (NAC) is a synthetic thiol which is readily able to
enter cells, increasing intracellular cysteine concentrations and
thereby enabling increased GSH synthesis.11
It has been suggested in experimental studies that NAC admin-
istration may reduce the extent of I/R injury with reported ben-
efits including reduced free radical formation, reduced bacterial
translocation from the gut, less microcirculatory disturbance and
less hepatic necrosis.12 Several clinical trials have examined the
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role of NAC in liver transplantation but there is a sparsity of
information related to its use in patients undergoing a hepatic
resection.13–15
The aim of this study was to determine what role, if any, NAC
might have in patients undergoing a hepatic resection with the key
outcome measures being post-operative morbidity and mortality.
Methods
Patient selection
Five surgeons perform liver resections within our unit, one of
whom (S.A.W.) routinely uses NAC in the post-operative period
in an attempt to reduce I/R injury. The treatment arm in this study
therefore consisted of 44 patients operated by this surgeon with
the control arm consisting of 44 patients operated by the other
surgeons between January 2005 and May 2010. Patients in the
control arm were selected using the prospectively maintained unit
database and were matched with the treatment arm for extent of
resection, use of pre-operative chemotherapy and histological
diagnosis.
Patient management
Patients undergoing a right or left trisectionectomy received pre-
operative bacterial gut decontamination (neomycin 1 g qds; nys-
tatin 1 million units qds; colistin 500 mg qds).All procedures were
performed under low CVP anaesthesia with intermittent portal
triad clamping utilized as necessary to minimize blood loss during
parenchymal transection. The arterial and portal venous inflow
were ligated prior to commencing parenchymal transection.
Neither total vascular occlusion nor ischaemic pre-conditioning
were utilized on any patient included within this series. Parenchy-
mal transection was performed in all cases using a CUSA EXcel
device (Integra Life Science, St Priest, France).
Post-operative care followed standard unit protocols in both
groups other than for the addition of NAC in the treatment group.
An infusion of NAC (10 g/24 h in 250 ml of 5% dextrose) was
commenced at the time of parenchymal transection and contin-
ued post-operatively for 3 days or until a fall in the post-operative
alanine aminotransferase (ALT).
Data collection
A prospectively maintained electronic database was used to
retrieve demographic details, histological diagnosis and post-
operative complications. The hospital laboratory database was
searched to retrieve pre- and post-operative blood results i.e. pro-
thrombin time (PT), bilirubin and ALT. Histology reports were
reviewed for all patients to identify the presence of background
parenchymal injury.
PHLF was defined as an elevation of bilirubin (range 0–21 mg/
dl) and PT (range 10–13 s) above the upper limit of normal on
post-operative day 5 or beyond. In patients where these values
were elevated pre-operatively, a failure to return to pre-operative
levels by day 5 was considered to be diagnostic of PHLF. The
severity of PHLF was graded according to a recent consensus
paper.16 Only grade B or C liver failure were considered to repre-
sent a complication of surgery as grade A PHLF does not require,
by definition, any change to patient management.
A major hepatectomy was defined as a resection of 3 or more
Couinaud segments (i.e. right or left hemi-hepatectomy and tri-
sectionectomy). The presence of background parenchymal liver
injury was determined from histology reports and was defined as
the presence of steatosis >30%, steatohepatitis, sinusoidal injury
(sinusoidal dilatation, nodular regenerative hyperplasia and hepa-
tocyte atrophy) or fibrosis.
Statistical analysis
Discrete variables were assessed for statistical significance using
the Chi-squared test. Continuous data are expressed as median
(range) and were compared using a two-tailed Mann Whitney
U-test.
Changes in post-operative ALT, bilirubin and PT were assessed
by treatment group using a two-way anova as previously
described by Clavien et al.17 Differences in values at individual
time points were assessed using Bonferroni’s post test. In the case
of missing data for a given time point, those individuals were
excluded from the analysis. All analysis was performed using
GraphPad PRISM (GraphPad, La Jolla, CA, USA). A P-value of
less than 0.05 was considered statistically significant.
Results
Patient characteristics
Both control and NAC treatment groups contained 44 patients
which were well matched in regard to gender (n = 30 versus n = 34
males) and median age [69.5 (40–84) versus 66.5 (42–81) years].
In both groups the main indication for surgery was colorectal liver
metastases (n = 38 per group). The proportion of patients who
received pre-operative systemic chemotherapy (n = 31 versus n =
30) and underwent a major hepatectomy (n = 38 versus n = 39)
was similar between groups. The median duration of portal triad
clamping was similar between the groups [30.0 (15–60) versus
26.0 (8–65) min]. There was a numerically higher incidence of
parenchymal injury overall in the NAC group (n = 21 versus n =
16) although this difference was not statistically significant.While
there was a tendency to a longer hospital stay in the NAC group
this difference was not statistically significant [13.5 (4–62) versus
11.0 (6–31) days; P = 0.0976] (Table 1). The time interval between
cessation of chemotherapy and surgery was greater than 6 weeks
for all patients.
Post-operative liver function
Serum ALT, bilirubin and PT were recorded pre-operatively and
on post-operative days 3, 5 and 7 as markers of hepatocellular
injury (ALT) and hepatocyte synthetic and excretory functions
(PT and bilirubin). The control and NAC treated groups did not
differ significantly in baseline ALT [26.5 (10–105) versus 28.0
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(9–104) u/l; P = 0.77; Fig. 1a], PT [12 (10–15) versus 11 (10–15) s;
P = 0.877; Fig. 1b] or bilirubin (9 (4–53) versus 8 (3–28) mg/dl;
P = 0.0666; Fig. 1c].
In both patient groups, hepatocellular injury, as measured by a
rise in serum ALT, peaked on post-operative day 3 with a decline
towards baseline values on day 7. NAC treatment was associated
with a lower post-operative ALT level as assessed by two-way
anova (P = 0.019) with this difference being most marked on
post-operative day 3 [308 (91–1599) versus 223 (74–764) u/l;
P < 0.01].
Whereas ALT provides a useful measure of hepatocellular
injury, it provides little information about hepatocyte function
and for this reason we compared PT and bilirubin between groups
on days 3, 5 and 7. Changes in PT mirrored those seen with ALT
but on this occasion there was no overall difference in PT values
according to treatment group as assessed by two-way anova (P =
0.104). Nonetheless, it was noted that the PT value on post-
operative day 3 appeared to be markedly shorter in the control
group as compared with those treated with NAC [16 (11–30)
versus 18 (13–26) s] with this difference being statistically signifi-
cant as judged by a Mann–Whitney U-test (P = 0.002).
Serum bilirubin was elevated to a similar degree in both the
control and NAC treated groups on post-operative day 3 [30
(9–116) versus 28 (8–120) mg/dl; P = 0.781]. Day 3 represented
the peak in serum bilirubin in the control group (Fig. 1c) whereas
in the NAC group the elevation persisted on day 5 [25 (7–43)
versus 36 (11–168) mg/dl; P = 0.192] and day 7 [24 (6–161) versus
27 (6–212) mg/dl; P = 0.3661] although the individual differences
were not significant at any time point. There was no overall effect
of NAC on bilirubin as judged by two-way anova (P = 0.152).
Complications
The incidence of PHLF of all grades was greater in those patients
receiving NAC (n = 17; 38.6%) as compared with controls (n = 10;
Table 1 Summary of patient demographics
Control (n = 44) NAC (n = 44) P-value
Gender
Male 30 (68.2%) 34 (77.3%) (77.3%) 0.473
Female 14 (31.8%) 10 (22.7%)
Age at time of surgery
Median age (years) 69.5 66.5 0.960
Indication for surgery
Colorectal liver metastases 38 (86.4%) 38 (86.4%)
Hepatocellular carcinoma 1 (2.3%) 3 (6.8%)
Adenocarcinoma gallbladder 2 (4.5%) 1 (2.3%) 0.598
Cholangiocarcinoma 2 (4.5%) 1 (2.3%)
Neuroendocrine metastases 1 (2.3%) —
Adenosquamous carcinoma — 1 (2.3%)
Pre-operative chemotherapy
Yes n = 31 (70.5%) n = 30 (68.2%) 1.00
No n = 13 (29.5%) n = 14 (31.8%)
Extent of surgery
Major hepatectomy 38 (86.4%) 39 (88.6%) 1.00
Minor hepatectomy 6 (13.6%) 5 (11.4%)
Portal triad clamping
Median duration (min) 30.0 26.0 0.600
Parenchymal injury
All 16 (36.4%) 21 (47.7%) 0.194
Steatosis > 30% 7 (15.9%) 8 (18.2%) 0.500
Steatohepatitis 0 (0%) 1 (2.3%) 0.500
Sinusoidal injury 13 (29.5%) 9 (20.5%) 0.230
Fibrosis 1 (2.3%) 1 (2.3%) 0.756
Length of hospital stay
Median stay (days) 11.0 13.5 0.098
NAC, N-acetylcysteine.
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22.7%; P = 0.165) although this difference did not reach statistical
significance. There was a preponderance of grade A PHLF in the
NAC group (n = 14, 31.8%) as compared with the controls (n = 4,
9%; P = 0.025) which appeared to be a result of the tendency
towards a prolonged PT in this patient group. The incidence of
clinically relevant grade B or C fistulae did not differ significantly
between the NAC (n = 3, 6.9%) and control (n = 6; 13.6%; P =
0.484) groups (see Table 2). Limiting the analysis to only those
patients undergoing a major hepatic resection had no effect on
results.
There was no statistically significant difference in the incidence
of patients experiencing clinically important complications (i.e.
Dindo-Clavien grade 2 or greater) between the NAC group (n =
11, 25%) and controls (n = 14, 31.8%; P = 0.318). There were two
peri-operative deaths in the NAC group as compared (Table 3)
with one in the control group (P = NS). All three deaths were a
consequence of multi-organ failure secondary to sepsis in patients
who developed grade C liver failure.
Discussion
It has long been known that hepatic I/R injury is, in part,mediated
by the generation of reactive oxygen species (ROS) which is asso-
ciated with the depletion of hepatic GSH.18 The ability of NAC to
replenish hepatic GSH levels has led to its use in several experi-
mental models of hepatic I/R where it has been demonstrated to
reduce the extent of liver injury.9,19,20 In particular, the use of NAC
in experimental I/R results in less ROS-mediated DNA damage,21
less lipid peroxidation21 and a reduction in ROS-mediated activa-
tion of the pro-inflammatory transcription factor NF-kB.22,23
At a functional level, NAC has been shown to improve the
hepatic microcirculation after experimental I/R injury with a sig-
nificant reduction in the number of non-perfused sinusoids.24–26
Similar findings have also been reported in experimental models
of orthotopic liver transplantation (OLT).27 It has been proposed
that this may be a result of the direct protective effects of NAC on
the sinusoidal endothelium which results in endothelial shedding
of selectins and reduced circulating levels of the adhesion mol-
ecules ICAM-1 and VCAM-1.15,28
In spite of the considerable experimental evidence suggesting a
potential role for NAC in reducing the complications associated
with hepatic resection this is the first publication to explore its role
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Figure 1 Changes in alanine aminotransferase (ALT) (a), prothrombin
time (PT) (b) and bilirubin (c) from baseline after a liver resection in
patients receiving peri-operative N-acetylcysteine (NAC) or matched
controls. Data presented as median interquartile range. (* =Mann–
Whitney U test)
Table 2 Grade of post-hepatectomy liver failure according to the
ISGLS consensus statement
Grade of PHLF Control (n = 44) NAC (n = 44) P-value
None 34 (77.3%) 27 (61.3%) 0.165
A 4 (9.1%) 14 (31.8) 0.025
B or C 6 (13.6%) 3 (6.9%) 0.484
NAC, N-acetylcysteine; PHLF, post-hepatectomy liver failure.
Table 3 Complications classified according to the Dindo-Clavien
method
Clavien-Dindo grade Control (n = 44) NAC (n = 44)
1 2 (4.5%) 12 (27.3%)
2 4 (9.1%) 4 (9.1%)
3 6 (13.6%) 4 (9.1%)
4 3 (6.8%) 1 (2.3%)
5 1 (2.3%) 2 (4.5%)
Grade 1 complications in each group consisted of exclusively grade A
PHLF which did not result in a change to patient management.
PHLF, post-hepatectomy liver failure.
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in this setting.12 Several small trials have explored the role of NAC
in reducing graft dysfunction after OLT. The most consistently
reported end point in these previous studies is liver function and
in most studies NAC is associated with a lower peak in serum
transaminase levels after OLT29,30 although this is not reflected in
all studies.31 It has also been observed that the use of NAC may be
associated with a lower incidence of primary non-function29 and
less severe rejection as compared with controls.30
In this study, we have shown that in patients undergoing an
elective hepatic resection the use of NAC does not appear to be
associatedwith a reduction in hepatocellular injury asmeasured by
serum ALT levels. Overall, NAC-treated patients experienced a
higher frequency of PHLF which was predominantly of grade A
and appeared to be a consequence of the more exaggerated
increases inpost-operative serumbilirubin in this group.Therewas
a trend towards a lower incidence of clinically significant PHLF
(grades B & C) and overall complications in NAC-treated patients
although these differences did not reach statistical significance.
NAC administration was associated with a statistically signifi-
cant prolongation of the PT on post-operative day 3 which
returned to match that of controls beyond this point. This reso-
lution is consistent with the cessation of drug infusion in the
majority of patients. NAC has been previously reported to result
in a prolonged PT in healthy volunteers through direct effects on
the vitamin K-dependent clotting factors II,VII, IX and X.32,33 This
may occur as a result of NAC-mediated interruption of disulphide
bonds necessary for the function of these clotting factors.34 As a
result of these and other studies, caution has been advised in
making the assumption that a prolonged PT equates to impaired
liver function in patients being treated with NAC.35
Patients in this study did not undergo a formal assessment of
the functional reserve of the liver such as the LiMAx test or meas-
urement of the indiocyanine green retention rate.36,37 Patients who
have received pre-operative chemotherapy therapy are more likely
to have an elevated indiocyanine green retention rate, particularly
in the context of oxaliplatin-induced sinusoidal injury.38,39 It is
known that oxaliplatin-based chemotherapy can result in deple-
tion of intracellular GSH perhaps thereby increasing the suscep-
tibility of these patients to ROS-mediated liver injury.40 It may be
that the focused use of peri-operative NAC in this cohort may
prove to be beneficial.
In summary, in this study we were not able to demonstrate any
evidence in support of the routine administration of NAC after a
liver resection.While it may be possible that our study was under-
powered to detect a true protective effect of NAC, it may also be
that our inclusion criteria were too broad. Further studies may be
better served to focus on those patients at a higher risk of PHLF
such as those undergoing a more extensive resection, particularly
with a background of significant parenchymal disease.
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